Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference
August 02, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a...
Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
June 26, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, June 26, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a Special Protocol Assessment (“SPA”) request...
Lipocine Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate
June 19, 2017 16:00 ET
|
Lipocine, Inc.
LPCN 1021 achieved primary endpoints confirming the efficacy of twice daily oral administration LPCN 1021 generally met the pre-specified per dose secondary endpoints for twice daily oral...
Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021
June 19, 2017 12:02 ET
|
Lipocine, Inc.
SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast today,...
Lipocine to Present at the Jefferies 2017 Healthcare Conference
June 02, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, and Morgan...
Lipocine Announces Financial and Operational Results for the First Quarter 2017
May 08, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, May 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2017. First...
Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials
April 24, 2017 08:00 ET
|
Lipocine, Inc.
Top-line data from the studies expected in June 2017 SALT LAKE CITY, April 24, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the...
Lipocine to Present at 16th Annual Needham Healthcare Conference
March 28, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, March 28, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Lipocine to Present at 27th Annual Oppenheimer Conference
March 14, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, March 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Lipocine Announces Financial and Operational Results for the Full Year of 2016
March 06, 2017 16:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended...